1. Unnikrishnan R, Pradeepa R, Joshi SR, Mohan V. Type 2 diabetes: demystifying the global epidemic. Diabetes 2017; 66(6): 1432-1442. https://doi.org/10.2337/db16-0766
2.
International Diabetes Federation. IDF diabetes atlas, 7th edition. Brussels: International Diabetes Federation; 2015.
3.
Fowler M. Hyperglycemic crisis in adults: pathophysiology, presentation, pitfalls, and prevention. Clinical Diabetes. 2009; 27(1): 19-23. https://doi.org/10.2337/diaclin.27.1.19
4.
Nathan DM, Bennett PH, Crandall JP, Edelstein SL, Goldberg RB, Kahn SE, et al. Does diabetes prevention translate into reduced long-term vascular complications of diabetes?. Diabetologia. 2019; 62: 1319-1328. https://doi.org/10.1007/s00125-019-4928-8
5.
Dávila AM, Escobar GF, Christian J, Silva L. [Summaries of free papers from the XVI Congress, 2018, of the Mexican Association of Transfusion Medicine]. Mexican Association of Transfusion Medicine. 2018; 11(Supl. 1): S3-S34.
6.
Care D. Standards of medical care in diabetes 2019. Diabetes Care. 2019; 42(Suppl 1): S124-38. https://doi.org/10.2337/dc19-S011
7.
Rodriguez-Gutierrez R, Gonzalez-Gonzalez JG, Zuñiga-Hernandez JA, McCoy RG. Benefits and harms of intensive glycemic control in patients with type 2 diabetes. BMJ. 2019; 367: l5887. https://doi.org/10.1136/bmj.l5887
8.
Andari E, Atallah P, Azar S, Echtay A, Jambart S, Saab C, et al. Experts’ opinion on the detection and management of prediabetes in Lebanon. Science Progress. 2021; 104(3): 00368504211029439. https://doi.org/10.1177/00368504211029439
9.
Higashikawa T, Ito T, Mizuno T, Ishigami K, Kohori M, Mae K, et al. The effects of 12-month administration of tofogliflozin on electrolytes and dehydration in mainly elderly Japanese patients with type 2 diabetes mellitus. Journal of International Medical Research. 2018; 46(12): 5117-5126.
10.
World Health Organization. World Health Statistics 2016 [OP]: Monitoring Health for the Sustainable Development Goals (SDGs). Geneva: World Health Organization; 2016.
11.
IDF. IDF diabetes atlas. 8th edition. Brussels: International Diabetes Federation; 2017. p. 905-911.
12.
Committee TI. International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care. 2009; 32(7): 1327. https://doi.org/10.2337/dc09-9033
13.
Dave R, Davis R, Davies JS. The impact of multiple lifestyle interventions on remission of type 2 diabetes mellitus within a clinical setting. Obesity Medicine. 2019; 13: 59-64. https://doi.org/10.1016/j.obmed.2019.01.005
14.
Pozzilli P, Strollo R, Bonora E. One size does not fit all glycemic targets for type 2 diabetes. Journal of Diabetes Investigation. 2014; 5(2): 134-41. https://doi.org/10.1111/jdi.12206
15.
Stumvoll M, Goldstein BJ, van Haeften TW. Pathogenesis of type 2 diabetes. Type 2 Diabetes. 2016: 27-40. https://doi.org/10.1080/07435800701743810
16.
Vargas-Vázquez A, Bello-Chavolla OY, Ortiz-Brizuela E, Campos-Muñoz A, Mehta R, Villanueva-Reza M, et al. Impact of undiagnosed type 2 diabetes and pre-diabetes on severity and mortality for SARS-CoV-2 infection. BMJ Open Diabetes Research and Care. 2021; 9(1): e002026. https://doi.org/10.1136/bmjdrc-2020-002026
17.
Engelgau MM, Narayan KM, Herman WH. Screening for type 2 diabetes. Diabetes Care. 2000; 23(10): 1563-80. https://doi.org/10.2337/diacare.23.10.1563
18.
Henry RR, Scheaffer L, Olefsky JM. Glycemic effects of intensive caloric restriction and isocaloric refeeding in noninsulin-dependent diabetes mellitus. The Journal of Clinical Endocrinology & Metabolism. 1985; 61(5): 917-925. https://doi.org/10.1210/jcem-61-5-917
19.
Bhandari R, Armenian SH, McCormack S, Natarajan R, Mostoufi-Moab S. Diabetes in childhood cancer survivors: emerging concepts in pathophysiology and future directions. Frontiers in Medicine. 2023; 10. https://doi.org/10.3389/fmed.2023.1206071
20.
Pan A, Sun Q, Bernstein AM, Manson JE, Willett WC, Hu FB. Changes in red meat consumption and subsequent risk of type 2 diabetes mellitus: three cohorts of US men and women. JAMA Internal Medicine. 2013; 173(14): 1328-1335. https://doi.org/10.1001/jamainternmed.2013.6633
21.
Emerging Risk Factors Collaboration. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. The Lancet. 2010; 375(9733): 2215-2222. https://doi.org/10.1016/S0140-6736(10)60484-9
22.
Albajy MA, Mihailescu D, Alexandra M, Maranda I. Prevalence of metabolic syndrome in people with type 2 diabetes in Romania. Journal of Biosciences and Medicines. 2023; 11(5): 247-268. https://doi.org/10.4236/jbm.2023.115018
23.
Leon BM, Maddox TM. Diabetes and cardiovascular disease: epidemiology, biological mechanisms, treatment recommendations and future research. World Journal of Diabetes. 2015; 6(13): 1246. https://doi.org/10.4239/wjd.v6.i13.1246
24.
Ogurtsova K, Guariguata L, Barengo NC, Ruiz PL, Sacre JW, Karuranga S, et al. IDF diabetes atlas: global estimates of undiagnosed diabetes in adults for 2021. Diabetes Research and Clinical Practice. 2022; 183: 109118. https://doi.org/10.1016/j.diabres.2021.109118
25.
IDF. IDF diabetes atlas. Brussels: International Diabetes Federation; 2013.
26.
Guariguata L, Whiting DR, Hambleton I, Beagley J, Linnenkamp U, Shaw JE. Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Research and Clinical Practice. 2014; 103(2): 137-149. https://doi.org/10.1016/j.diabres.2013.11.002
27.
Baynes HW. Classification, pathophysiology, diagnosis and management of diabetes mellitus. J Diabetes Metab. 2015; 6(5): 1-9.
28.
Scheepers A, Joost HG, Schurmann A. The glucose transporter families SGLT and GLUT: molecular basis of normal and aberrant function. Journal of Parenteral and Enteral Nutrition. 2004; 28(5): 364-371. https://doi.org/10.1177/0148607104028005364
29.
Thambisetty M, Metter EJ, Yang A, Dolan H, Marano C, Zonderman AB, et al. Glucose intolerance, insulin resistance, and pathological features of Alzheimer disease in the Baltimore Longitudinal Study of Aging. JAMA Neurology. 2013; 70(9): 1167-72. https://doi.org/10.1001/jamaneurol.2013.284
30.
Matias I, Gonthier MP, Orlando P, Martiadis V, De Petrocellis L, Cervino C, et al. Regulation, function, and dysregulation of endocannabinoids in models of adipose and β-pancreatic cells and in obesity and hyperglycemia. The Journal of Clinical Endocrinology & Metabolism. 2006; 91(8): 3171-3180. https://doi.org/10.1210/jc.2005-2679
31.
Yahia N, Brown CA, Snyder E, Cumper S, Langolf A, Trayer C, et al.. Prevalence of metabolic syndrome and its individual components among Midwestern university students. Journal of Community Health. 2017; 42: 674-687. https://doi.org/10.1007/s10900-016-0304-5
32.
Patel TP, Rawal K, Bagchi AK, Akolkar G, Bernardes N, Dias DD, et al. Insulin resistance: an additional risk factor in the pathogenesis of cardiovascular disease in type 2 diabetes. Heart Failure Reviews. 2016; 21: 11-23. https://doi.org/10.1007/s10741-015-9515-6
33.
Mousavi SE, Shahriari A, Ahangarpour A, Vatanpour H, Jolodar A. Effects of teucrium polium ethyl acetate extract on serum, liver and muscle triglyceride content of sucrose-induced insulin resistance in rat. Iranian Journal of Pharmaceutical Research: IJPR. 2012; 11(1): 347.
34.
Stumvoll M, Ha HU. Metformin. Type 2 Diabetes. 2016; 121-34.
35.
Hirahatake KM, Meissen JK, Fiehn O, Adams SH. Comparative effects of fructose and glucose on lipogenic gene expression and intermediary metabolism in HepG2 liver cells. PLoS One. 2011; 6(11): e26583. https://doi.org/10.1371/journal.pone.0026583
36.
Rauchman MU, Wasserman JC, Cohen DM, Perkins DL, Hebert SC, Milford E, et al. Expression of GLUT-2 cDNA in human B lymphocytes: analysis of glucose transport using flow cytometry. Biochimica et Biophysica Acta (BBA)-Biomembranes. 1992; 1111(2): 231-238. https://doi.org/10.1016/0005-2736(92)90315-D
37.
Davidson MB, Schriger DL, Peters AL, Lorber B. Relationship between fasting plasma glucose and glycosylated hemoglobin: potential for false-positive diagnoses of type 2 diabetes using new diagnostic criteria. Jama. 1999; 281(13): 1203-1210. https://doi.org/10.1001/jama.281.13.1203
38.
Andersson DK, Lundblad E, Svärdsudd K. A model for early diagnosis of type 2 diabetes mellitus in primary health care. Diabetic Medicine. 1993; 10(2): 167-173. https://doi.org/10.1111/j.1464-5491.1993.tb00036.x
39.
Meigs JB, Cupples LA, Wilson PW. Parental transmission of type 2 diabetes: the Framingham Offspring Study. Diabetes. 2000; 49(12): 2201-2207. https://doi.org/10.2337/diabetes.49.12.2201
40.
Robertson RP. Chronic oxidative stress as a central mechanism for glucose toxicity in pancreatic islet beta cells in diabetes. Journal of Biological Chemistry. 2004; 279(41): 42351-42354. https://doi.org/10.1074/jbc.R400019200
41.
Boland BB, Rhodes CJ, Grimsby JS. The dynamic plasticity of insulin production in β-cells. Molecular metabolism. 2017; 6(9): 958-73. https://doi.org/10.1016/j.molmet.2017.04.010
42.
Moin AS, Butler AE. Alterations in beta cell identity in type 1 and type 2 diabetes. Current Diabetes Reports. 2019; 19: 1-2. https://doi.org/10.1007/s11892-019-1194-6
43.
Weir GC, Laybutt DR, Kaneto H, Bonner-Weir S, Sharma A. Beta-cell adaptation and decompensation during the progression of diabetes. Diabetes. 2001; 50(suppl. 1): S154. https://doi.org/10.2337/diabetes.50.2007.S154
44.
Umpierrez G. Diabetic ketoacidosis and hyperglycemic hyperosmolar syndrome. Clinical Diabetes. 2006; 101-118. https://doi.org/10.1016/B978-1-4160-0273-4.50014-X
45.
Volek JS, Sharman MJ, Love DM, Avery NG, Scheett TP, Kraemer WJ. Body composition and hormonal responses to a carbohydrate-restricted diet. Metabolism-Clinical and Experimental. 2002; 51(7): 864-870. https://doi.org/10.1053/meta.2002.32037
46.
National Heart, Lung, Blood Institute, National Institute of Diabetes, Digestive, Kidney Diseases (US). Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: the evidence report. Bethesda: National Heart, Lung, and Blood Institute; 1998.
47.
Della Manna T, Steinmetz L, Campos PR, Farhat SC, Schvartsman C, Kuperman H, et al. Subcutaneous use of a fast-acting insulin analog: an alternative treatment for pediatric patients with diabetic ketoacidosis. Diabetes Care. 2005; 28(8): 1856-61. https://doi.org/10.2337/diacare.28.8.1856
48.
Kitabchi AE, Umpierrez GE, Miles JM, Fisher JN. Hyperglycemic crises in adult patients with diabetes. Diabetes Care. 2009; 32(7): 1335. https://doi.org/10.2337/dc09-9032
49.
Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. New England Journal of Medicine. 1993; 329(14): 977-986. https://doi.org/10.1056/NEJM199309303291401
50.
Mohajan D, Mohajan HK. Metformin: an oral anti-hyperglycaemic agent for the treatment of type 2 diabetes. Journal of Innovations in Medical Research. 2023; 2(11): 1-8. https://doi.org/10.56397/JIMR/2023.11.01
51.
Levin P, Hoogwerf BJ, Snell-Bergeon J, Vigers T, Pyle L, Bromberger L. Ultra rapid-acting inhaled insulin improves glucose control in patients with type 2 diabetes mellitus. Endocrine Practice. 2021; 27(5): 449-454. https://doi.org/10.1016/j.eprac.2020.10.004
52.
Woolfson AM. An improved method for blood glucose control during nutritional support. Journal of Parenteral and Enteral Nutrition. 1981; 5(5): 436-440. https://doi.org/10.1177/0148607181005005436
53.
Wilson PW, Cupples LA, Kannel WB. Is hyperglycemia associated with cardiovascular disease? The Framingham Study. American Heart Journal. 1991; 121(2): 586-590. https://doi.org/10.1016/0002-8703(91)90729-2
54.
Franz MJ, Zhang Z, Venn BJ. Nutrition therapy effectiveness for the treatment of type 1 and type 2 diabetes: prioritizing recommendations based on evidence. Nutrition Guide for Physicians and Related Healthcare Professionals. 2017: 91-102. https://doi.org/10.1007/978-3-319-49929-1_9
55.
Mendes BB, Oliveira AC, Alcântara KC. Comparison of the neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios in normoglycemic and hyperglycemic subjects. Einstein (Sao Paulo). 2019; 17: eAO4403. https://doi.org/10.31744/einstein_journal/2019AO4403
56.
Crowley MJ, McGuire DK, Alexopoulos AS, Jensen TJ, Rasmussen S, Saevereid HA, et al. Effects of liraglutide on cardiovascular outcomes in type 2 diabetes patients with and without baseline metformin use: post hoc analyses of the LEADER trial. Diabetes Care. 2020; 43(9): e108. https://doi.org/10.2337/dc20-0437
57.
Masson W, Lavalle-Cobo A, Lobo M, Masson G, Molinero G. Novel antidiabetic drugs and risk of cardiovascular events in patients without baseline metformin use: a meta-analysis. European Journal of Preventive Cardiology. 2021; 28(1): 69-75. https://doi.org/10.1093/eurjpc/zwaa074
58.
Matthews D, Del Prato S, Mohan V, Mathieu C, Vencio S, Chan JC, et al. Insights from VERIFY: early combination therapy provides better glycaemic durability than a stepwise approach in newly diagnosed type 2 diabetes. Diabetes Therapy. 2020; 11: 2465-2476. https://doi.org/10.1007/s13300-020-00926-7
59.
Lalau JD, Kajbaf F, Bennis Y, Hurtel-Lemaire AS, Belpaire F, De Broe ME. Metformin treatment in patients with type 2 diabetes and chronic kidney disease stages 3A, 3B, or 4. Diabetes Care. 2018; 41(3): 547-553. https://doi.org/10.2337/dc17-2231
60.
Out M, Kooy A, Lehert P, Schalkwijk CA, Stehouwer CD. Long-term treatment with metformin in type 2 diabetes and methylmalonic acid: post hoc analysis of a randomized controlled 4.3 year trial. Journal of Diabetes and its Complications. 2018; 32(2): 171-178. https://doi.org/10.1016/j.jdiacomp.2017.11.001
61.
Aroda VR, Edelstein SL, Goldberg RB, Knowler WC, Marcovina SM, Orchard TJ, et al. Long-term metformin use and vitamin B12 deficiency in the diabetes prevention program outcomes study. The Journal of Clinical Endocrinology & Metabolism. 2016; 101(4): 1754-1761. https://doi.org/10.1210/jc.2015-3754
62.
Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015; 38(1): 140-149. https://doi.org/10.2337/dc14-2441
63.
Sherr D, Lipman RD. The diabetes educator and the diabetes self-management education engagement: the 2015 National Practice Survey. The Diabetes Educator. 2015; 41(5): 616-24. https://doi.org/10.1177/0145721715599268
64.
Holden SE, Jenkins-Jones S, Currie CJ. Association between insulin monotherapy versus insulin plus metformin and the risk of all-cause mortality and other serious outcomes: a retrospective cohort study. PLoS One. 2016; 11(5): e0153594. https://doi.org/10.1371/journal.pone.0153594
65.
Bays HE, Bindlish S, Clayton TL. Obesity, diabetes mellitus, and cardiometabolic risk: an obesity medicine association (OMA) clinical practice statement (CPS) 2023. Obesity Pillars. 2023; 5: 100056. https://doi.org/10.1016/j.obpill.2023.100056
66.
Katsaridis S, Grammatikopoulou MG, Gkiouras K, Tzimos C, Papageorgiou ST, Markaki AG, et al. Low reported adherence to the 2019 American diabetes association nutrition recommendations among patients with type 2 diabetes mellitus, indicating the need for improved nutrition education and diet care. Nutrients. 2020; 12(11): 3516. https://doi.org/10.3390/nu12113516
67.
Simes BC, MacGregor GG. Sodium-glucose cotransporter-2 (SGLT2) inhibitors: a clinician’s guide. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy. 2019; 2125-36. https://doi.org/10.2147/DMSO.S212003
68.
Cho YM. Incretin physiology and pathophysiology from an A sian perspective. Journal of Diabetes Investigation. 2015; 6(5): 495-507. https://doi.org/10.1111/jdi.12305
69.
Fukuda M, Doi K, Sugawara M, Mochizuki K. Efficacy and safety of sitagliptin in elderly patients with type 2 diabetes mellitus: a focus on hypoglycemia. Journal of Diabetes Investigation. 2019; 10(2): 383-391. https://doi.org/10.1111/jdi.12915
70.
Shiomi M, Takada T, Tanaka Y, Yajima K, Isomoto A, Sakamoto M, et al. Clinical factors associated with the occurrence of nausea and vomiting in type 2 diabetes patients treated with glucagon‐like peptide‐1 receptor agonists. Journal of Diabetes Investigation. 2019; 10(2): 408-417. https://doi.org/10.1111/jdi.12900
71.
Kimura T, Obata A, Shimoda M, Shimizu I, da Silva Xavier G, Okauchi S, et al. Down-regulation of vascular GLP-1 receptor expression in human subjects with obesity. Scientific Reports. 2018; 8(1): 10644. https://doi.org/10.1038/s41598-018-28849-1
72.
Helmstädter J, Frenis K, Filippou K, Grill A, Dib M, Kalinovic S, et al. Endothelial GLP-1 (glucagon-like peptide-1) receptor mediates cardiovascular protection by liraglutide in mice with experimental arterial hypertension. Arteriosclerosis, Thrombosis, and Vascular Biology. 2020; 40(1): 145-58. https://doi.org/10.1161/atv.0000615456.97862.30
73.
Wang D, Jiang L, Feng B, He N, Zhang Y, Ye H. Protective effects of glucagon‐like peptide‐1 on cardiac remodeling by inhibiting oxidative stress through mammalian target of rapamycin complex 1/p70 ribosomal protein S6 kinase pathway in diabetes mellitus. Journal of Diabetes Investigation. 2020; 11(1): 39-51. https://doi.org/10.1111/jdi.13098
74.
Araszkiewicz A, Bandurska-Stankiewicz E, Borys S, Budzyński A, Cyganek K, Cypryk K, et al. 2021 Guidelines on the management of patients with diabetes. A position of Diabetes Poland. Clinical Diabetology. 2021; 10(1): 1-13. https://doi.org/10.5603/DK.2021.0001
75.
Monnier L, Colette C, Dunseath GJ, Owens DR. The loss of postprandial glycemic control precedes stepwise deterioration of fasting with worsening diabetes. Diabetes Care. 2007; 30(2): 263-269. https://doi.org/10.2337/dc06-1612
76.
Bastaki S. Diabetes mellitus and its treatment. Dubai Diabetes And Endocrinology Journal, 2005; 13(3): 111-134. https://doi.org/10.1159/000497580
77.
Cusi K, Isaacs S, Barb D, Basu R, Caprio S, Garvey WT, et al. American Association of Clinical Endocrinology clinical practice guideline for the diagnosis and management of nonalcoholic fatty liver disease in primary care and endocrinology clinical settings: co-sponsored by the American Association for the Study of Liver Diseases (AASLD). Endocrine Practice. 2022; 28(5): 528-562. https://doi.org/10.1016/j.eprac.2022.03.010
78.
Leichter S. Is the use of insulin analogues cost-effective?. Advances in Therapy. 2008; 25: 285-299. https://doi.org/10.1007/s12325-008-0043-9
79.
Busch RS, Kane MP. Combination SGLT2 inhibitor and GLP-1 receptor agonist therapy: a complementary approach to the treatment of type 2 diabetes. Postgraduate Medicine. 2017; 129(7): 686-697. https://doi.org/10.1080/00325481.2017.1342509
80.
Davies MJ, Aroda VR, Collins BS, Gabbay RA, Green J, Maruthur NM, et al. Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2022; 45(11): 2753-86. https://doi.org/10.2337/dci22-0034
81.
Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. The Lancet. 2019; 394(10193): 121-130.
82.
Chawla R, Madhu SV, Makkar BM, Ghosh S, Saboo B, Kalra S, et al. RSSDI-ESI Clinical Practice Recommendations for the management of type 2 diabetes mellitus. Indian Journal of Endocrinology and Metabolism. 2020; 24(1): 1-22. https://doi.org/10.4103/ijem.IJEM_225_20
83.
Burchi F, Fanzo J, Frison E. The role of food and nutrition system approaches in tackling hidden hunger. International Journal of Environmental Research and Public Health. 2011; 8(2): 358-373. https://doi.org/10.3390/ijerph8020358
Copyright: © 2024 Pope John Paul II State School of Higher Education in Biała Podlaska. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
